论文部分内容阅读
目的 探讨肿瘤浸润性淋巴细胞 (TIL)对原发性肝癌 (HCC)患者术后细胞免疫功能的影响和临床疗效及半乳糖抗CD3 单克隆抗体 TIL复合物 (Gal Anti CD3 McAb TIL)体外及体内的趋肝性。方法 (1)对 30例HCC患者术后进行了TIL和重组白介素 2 (rIL 2 )治疗。 (2 )制备半乳糖基抗CD3 单克隆抗体 TIL(McAb TIL)复合物。将TIL和McAb TIL分别与小鼠肝细胞置CO2 孵箱中孵育 ,用倒置相差显微镜观察其趋肝性。将12 5I TIL和12 5I McAb TIL分别经小鼠尾静脉注入 ,观察示踪剂在脏器中的分布。结果 TIL治疗后 ,30例患者外周血rIL 2、T细胞亚群均有上升。 2 4例肝癌根治性切除术患者随访 6～ 48个月无复发。McAb TIL与肝细胞有明显粘附 ,给小鼠静脉注射后 ,TIL和McAb TIL主要在肺中积聚 ,在肝内浓度较低。结论 TIL治疗可能提高HCC患者术后抗肿瘤细胞免疫功能。TIL与半乳糖抗CD3 单克隆抗体结合物体内肝靶向性不明显
Objective To investigate the effect and clinical efficacy of tumor-infiltrating lymphocytes (TIL) on postoperative cellular immune function in patients with primary hepatocellular carcinoma (HCC) and the in vitro and in vivo effects of galactose anti-CD3 monoclonal antibody TIL complex (Gal Anti CD3 McAb TIL). Hepatotropism. Methods (1) TIL and recombinant interleukin 2 (rIL 2 ) were performed on 30 patients with HCC. (2) Preparation of galactosyl anti-CD3 monoclonal antibody TIL (McAb TIL) complex. The TIL and McAb TIL were incubated with mouse liver cells in a CO2 incubator, and the hepatotropia was observed with an inverted phase contrast microscope. The 12 5I TIL and 12 5I McAb TILs were injected into the tail vein of mice, and the distribution of the tracer in the organs was observed. Results After TIL treatment, peripheral blood rIL 2 and T cell subsets increased in 30 patients. Two to four patients undergoing radical resection of liver cancer were followed up for 6 to 48 months without recurrence. The McAb TIL has obvious adhesion to hepatocytes. After intravenous injection to mice, TIL and McAb TIL mainly accumulate in the lung and have a low intrahepatic concentration. Conclusion TIL treatment may improve anti-tumor cellular immune function in HCC patients. The liver targeting of TIL and galactose anti-CD3 monoclonal antibody is not obvious